Tag
A phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.
Two complementary studies identify METTL14/TLR4 and LATS1/2–CD38–SUOX axes as key drivers of endothelial senescence phenotypes that promote arterial ageing, stiffness, fragile neovessels and atherothrombotic plaque formation, highlighting n
A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therape
